AIM Vaccine Co., Ltd. Class H (HK:6660)
:6660
Want to see HK:6660 full AI Analyst Report?
6660 Stock Chart & Stats
HK$3.49
-HK$0.02(-0.35%)
At close: 4:00 PM EST
HK$3.49
-HK$0.02(-0.35%)
Day’s Range― - ―
52-Week RangeHK$2.13 - HK$6.01
Previous CloseN/A
Volume905.00K
Average Volume (3M)1.38M
Market Cap
HK$2.71B
Enterprise ValueHK$3.87B
Total Cash (Recent Filing)HK$384.72M
Total Debt (Recent Filing)HK$1.76B
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding507,673,700
10 Day Avg. Volume830,500
30 Day Avg. Volume1,376,953
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.28
Price to Sales (P/S)3.03
P/FCF Ratio-20.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.6
Revenue Forecast (FY)HK$3.68B
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsSustained gross margins near 62%–74% indicate structurally favorable unit economics for vaccines and biologics. High product-level margins provide long-term capacity to fund R&D, commercial expansion and absorb pricing pressure, supporting durable profitability if operating costs are controlled.
Positive Operating Cash FlowConsistent positive operating cash flow across recent years shows the core business generates real cash from sales. That cash generation supports near-term operations, reduces reliance on new equity, and gives management flexibility to prioritize investments or debt repayment over the coming months.
Manageable Leverage LevelA 0.64 debt-to-equity ratio is moderate for a biotech manufacturer, leaving room to raise incremental debt if needed. With leverage at this level, the company retains structural financing flexibility to support production scaling or clinical programs without immediate solvency pressure.
Bears Say
Revenue DeclineA material revenue decline signals weakening commercial traction or procurement timing shifts for vaccine sales. Persisting top-line contraction over multiple quarters would erode scale benefits, strain margins and make it harder to cover fixed manufacturing and R&D costs over the next several months.
Deep Operating LossesVery negative margins and returns indicate operating costs and R&D/SG&A materially exceed revenue. Structural losses dilute equity, constrain reinvestment capacity, and raise the risk that management must cut programs or seek dilutive financing if profitable scale is not restored within the medium term.
Negative Free Cash FlowPersistent negative free cash flow demonstrates the business consumes cash after investments. Even with positive operating cash flow, ongoing capex or working capital needs create funding gaps that may require external financing, increasing dilution or leverage risk over the next 2–6 months.
AIM Vaccine Co., Ltd. Class H News
6660 FAQ
What was AIM Vaccine Co., Ltd. Class H’s price range in the past 12 months?
AIM Vaccine Co., Ltd. Class H lowest stock price was HK$2.13 and its highest was HK$6.01 in the past 12 months.
What is AIM Vaccine Co., Ltd. Class H’s market cap?
AIM Vaccine Co., Ltd. Class H’s market cap is HK$2.71B.
When is AIM Vaccine Co., Ltd. Class H’s upcoming earnings report date?
AIM Vaccine Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 89 days.
How were AIM Vaccine Co., Ltd. Class H’s earnings last quarter?
AIM Vaccine Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported -HK$0.486 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.486.
Is AIM Vaccine Co., Ltd. Class H overvalued?
According to Wall Street analysts AIM Vaccine Co., Ltd. Class H’s price is currently Overvalued.
Does AIM Vaccine Co., Ltd. Class H pay dividends?
AIM Vaccine Co., Ltd. Class H does not currently pay dividends.
What is AIM Vaccine Co., Ltd. Class H’s EPS estimate?
AIM Vaccine Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIM Vaccine Co., Ltd. Class H have?
AIM Vaccine Co., Ltd. Class H has 507,673,700 shares outstanding.
What happened to AIM Vaccine Co., Ltd. Class H’s price movement after its last earnings report?
AIM Vaccine Co., Ltd. Class H reported an EPS of -HK$0.486 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.667%.
Which hedge fund is a major shareholder of AIM Vaccine Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6660
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AIM Vaccine Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.69%
12-Months-Change
Fundamentals
Return on Equity
-22.28%
Trailing 12-Months
Asset Growth
-6.35%
Trailing 12-Months
Company Description
AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People's Republic of China. The company's product pipeline includes Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA, which is in phase III clinical trails for the treatment of COVID-19; EV71-CA16 Bivalent for HFMD; and Valent Pneumococcal Conjugate and Polysaccharide vaccine for pneumococcal disease. It also offers Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine for Group B strep disease; Diphtheria, Tetanus and Pertussis and Haemophilus In¬uenzae type B, and Diphtheria, Tetanus and Acellular Pertussis, and Absorbed Tetanus for DTP; Haemophilus In¬uenzae Type B for Hib; and freeze-dried human rabies and mRNA human rabies vaccine. In addition, the company develops Human Papillomavirus 2 and 3-valent vaccine; Tetravalent Meningococcal Conjugate vaccine; Tetravalent In¬uenzae vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; live attenuated parotitis vaccine; and ACYW135 meningococcal polysaccharide vaccine. The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. AIM Vaccine Co., Ltd. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Lepu Biopharma Co. Ltd. Class H
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---